Click on image to view larger version.

Figure 1 Primary efficacy analysis. Time to symptomatic arrhythmia recurrence was significantly longer in the combined azimilide 100 mg QD and 125 mg QD dose group compared with the placebo group (chi-square 7.96, p = 0.005). QD = daily.